Modulating Agonistic TNFR Antibodies
AssigneeThe Rockefeller University
InventorsJeffrey V. Ravetch, Fubin Li
Life of this patent
Estimating the term…
Abstract
The instant invention relates to agents (e.g., agonistic antibodies) able to stimulate the immune system of a mammalian animal and activate target-cell specific T lymphocyte responses. Such agents may be identified based on the ability to engage a receptor from the TNFR Superfamily and thereby mimic the natural ligand for the receptor from the TNFR Superfamily. Modified antibodies of this class display enhanced immunostimulatory activity and may be formulated and administered for the treatment of a disease or disorder.
Claims15
1-11. (canceled)
A method for making an agonistic antibody against a TNFR superfamily receptor, the method comprising:
- providing a starting antibody or a first nucleic acid sequence encoding a polypeptide chain of the starting antibody;
- and
- modifying the starting antibody to obtain a modified antibody so that the modified antibody has a higher binding affinity to an inhibitory Fcγ receptor, as compared to the starting antibody.
21-55. (canceled)
Dependencies are inferred from the claim text.